article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.

article thumbnail

In Brain Chemistry We Trust—The Gospel According to Pharma

Mad in America

Depression was sold to us as a simple problem of serotonin insufficiency, a convenient narrative that made drug companies like Eli Lilly, Forest Pharmaceuticals, and Pfizer very rich. As a former pharmaceutical advertising writer, I not only witnessed the explosive growth in antidepressant drugs, I contributed to it.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

June in Review: Updates on the Psychiatric Treatment Pipeline

Psychiatric Times

NRx Pharmaceuticals seeks FDA approval for NRX-100, a preservative-free ketamine for suicidal depression and PTSD, via the National Priority Voucher pathway. A recently filed patent on its preservative-free manufacturing process may further support market exclusivity.

article thumbnail

Centanafadine Study: New ADHD Drug Effective for Adults and Kids

ADDitude

June 24, 2025 Centanafadine — a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) — is effective at treating ADHD in adults, adolescents, and children, according to Phase 3 trials sponsored by the drug’s manufacturer, Otsuka Pharmaceuticals.

article thumbnail

The Editorial Demise of Psychotherapy and Psychosomatics Is Bad News For Us All

Mad in America

The journal continued to be in good hands, and thus one of the few journals that was receptive to research findings that belied the narrative of therapeutic progress that the psychiatric guild and pharmaceutical companies have been promoting for decades. He noted too the reluctance of the field to consider this possibility.

article thumbnail

Do Critics of Biological Psychiatry Have an Alternative to a Life of “Whack-A-Mole”?

Mad in America

Establishment psychiatry has shown this same unscientific thinking in its manufacturing of other biological theories of mental illness. The APA publishes the DSM diagnostic manual, and PLOS Medicine reported in 2012, 69% of the DSM- 5 task force members report having ties to the pharmaceutical industry.

article thumbnail

Akathisia After a Five-Year Taper: Chained to an Antidepressant Forever

Mad in America

My brain and my life are dependent upon a pharmaceutical company in India staying in business and manufacturing generic duloxetine until the day I die. I also get withdrawal if I try to switch brands, and I have no idea if my brain would eventually accept and stabilize on a new brand.